Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Hepatocellular 8Melanoma 4Uveal Melanoma 3Sarcoma 3Leukemia, Myeloid, Acute 3Glioblastoma 3Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Neoplasms 2Mesothelioma, Malignant 2Glioma 2Carcinoma, Non-Small-Cell Lung 2Stomach Neoplasms 1Skin Neoplasms 1Resectable Hepatocellular Carcinoma 1Recurrence 1Ovarian Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Liver Neoplasms 1Leiomyosarcoma 1Ichthyosis, X-Linked 1HER2 Negative Metastatic Breast Cancer 1Colorectal Neoplasms 1Carcinoma 1Advanced Solid Cancers 1Advanced Pancreatic Cancer 1

Interventions

Etoposide 154Carboplatin 142Cisplatin 104Topotecan 74durvalumab 48atezolizumab 46Irinotecan 44pembrolizumab 39Paclitaxel 34Nivolumab 33Radiotherapy 29anlotinib 23PM 01183 22Gemcitabine 21Drug Therapy 20apatinib 19Ipilimumab 18Docetaxel 17Temozolomide 16Platinum 16Radiosurgery 15Pemetrexed 14toripalimab 13tislelizumab 13olaparib 13Bevacizumab 13amrubicin 11Magnetic Resonance Spectroscopy 11Cyclophosphamide 11rovalpituzumab tesirine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Small Cell Lung Carcinoma × ADI PEG20 × Clear all
NCT05616624 2026-04-15

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

Washington University School of Medicine

Phase 1/2 Active not recruiting
31 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT01266018 2022-10-25

Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer

Ludwig Institute for Cancer Research

Phase 2 Terminated
22 enrolled 14 charts
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡